The alpha-particle-emitting radionuclides 213Bi, 211At, 224Ra are under investigation for
the treatment of leukemias, gliomas, and ankylosing spondylitis, respectively. 213Bi and
211At were attached to monoclonal antibodies and used as targeted immunotherapeutic
agents while unconjugated 224Ra chloride selectively seeks bone. 225Ac possesses
favorable physical properties for radioimmunotherapy (10d half-life and 4 net alpha
particles), but has a history of unfavorable radiolabeling chemistry and poor metal-chelate …